Omnicare: Omnicare Makes Donation to the Neurodegeneration Consortium to
Advance the Study and Treatment of Alzheimer's
CINCINNATI, May 23, 2014 - Omnicare, Inc. (NYSE: OCR) today announced a
$50,000 donation to the Neurodegeneration Consortium (NDC), a collaboration of
The University of Texas MD Anderson Cancer Center, Baylor College of Medicine
and the Massachusetts Institute of Technology. The NDC is a transformative
initiative to advance the study and treatment of Alzheimer's and other
"Our organization plays a critical role in improving the quality of care for
those afflicted with neurodegenerative diseases," said Nitin Sahney,
Omnicare's President and Chief Operating Officer. "We are pleased to have the
opportunity to partner with this initiative whose work is parallel to our
services and core values, and to contribute to the community in a meaningful
The NDC's mission is to identify key molecular targets that cause Alzheimer's
and other neurodegerative diseases and to rapidly translate these discoveries
into treatments. Recent research has revealed common molecular themes in
neurodegeneration, cancer and other age-associated diseases.
"We are deeply grateful to Omnicare for supporting the NDC's efforts to
understand and overcome one of the greatest challenges facing humanity in this
century," said Ron DePinho, M.D., president of MD Anderson. "Our aim is to
find out how and why neurodegenerative diseases develop and to find the key
steps to prevent or slow disease progression, while addressing quality of life
issues and the financial challenges of living with Alzheimer's disease,
Parkinson's disease and chemotherapy induced neuropathy. Philanthropy is the
driving force behind this initiative, and Omnicare's generous gift of $50,000
is a much-needed boost to the NDC and its unique approach."
The donation is funded by the Omnicare Foundation, a nonprofit whose mission
is to improve health and to support organizations that make a positive
difference in the lives of individuals in the communities that we serve.
Omnicare, Inc., a Fortune 500 company based in Cincinnati, Ohio, provides
comprehensive pharmaceutical services to patients and providers across the
United States. As the market-leader in professional pharmacy, related
consulting and data management services for skilled nursing, assisted living
and other chronic care institutions, Omnicare leverages its unparalleled
clinical insight into the geriatric market along with some of the industry's
most innovative technological capabilities to the benefit of its long-term
care customers. Omnicare also provides key commercialization services for the
bio-pharmaceutical industry through its Specialty Care Group. For more
information, visit www.omnicare.com.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of
the world's most respected centers focused on cancer patient care, research,
education and prevention. MD Anderson is one of only 41 comprehensive cancer
centers designated by the National Cancer Institute. For 10 of the past 12
years, including 2013, MD Anderson has ranked No. 1 in cancer care in "Best
Hospitals," a survey published annually in U.S. News & World Report. MD
Anderson receives a cancer center support grant from the National Cancer
Institute of the National Institutes of Health (P30 CA016672).
# # #
Patrick C. Lee
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: Omnicare via Globenewswire
Press spacebar to pause and continue. Press esc to stop.